A carregar...
P01.116 Treatment with Dabrafenib in a patient with BRAF mutated recurrent ganglioglioma
BACKGROUND: Gangliogliomas are rare tumor usually arising in the supratentorial region, WHO grade 1 or 2. In these tumors, BRAF mutation may constitute a driver genetic alteration and a biomarker of response to BRAF inhibitors. Dabrafenib is an oral inhibitor of BRAF and has shown to significantly i...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144130/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.158 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|